Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
2.910
-0.010 (-0.34%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Can-Fite BioPharma Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 6 | 25 | 16 | 9 | 19 | 39 | |
| Market Cap Growth | -62.06% | 58.34% | 75.98% | -54.62% | -49.45% | 34.30% | |
| Enterprise Value | -3 | 18 | 11 | 0 | 9 | 24 | |
| Last Close Price | 2.91 | 4.00 | 32.50 | 44.00 | 122.60 | 258.00 | |
| PS Ratio | 15.91 | 60.84 | 23.09 | 11.90 | 24.06 | 45.20 | |
| PB Ratio | 1.15 | 4.41 | 2.86 | 1.42 | 4.36 | 2.68 | |
| P/TBV Ratio | 1.15 | 4.41 | 2.86 | 1.42 | 4.36 | 2.68 | |
| EV/Sales Ratio | - | 44.23 | 15.92 | 0.65 | 10.63 | 28.70 | |
| Debt / Equity Ratio | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Net Debt / Equity Ratio | -1.51 | -1.51 | -1.43 | -1.42 | -1.77 | -1.32 | |
| Net Debt / EBITDA Ratio | 0.85 | 0.85 | 0.96 | 1.09 | 0.79 | 1.48 | |
| Net Debt / FCF Ratio | 0.95 | 0.95 | 1.02 | 1.05 | 0.73 | 1.93 | |
| Asset Turnover | 0.04 | 0.04 | 0.07 | 0.08 | 0.06 | 0.06 | |
| Quick Ratio | 3.13 | 3.13 | 3.84 | 4.42 | 3.19 | 7.01 | |
| Current Ratio | 3.46 | 3.46 | 4.38 | 4.91 | 3.66 | 7.35 | |
| Return on Equity (ROE) | -178.24% | -178.24% | -134.94% | -142.49% | -107.91% | -123.34% | |
| Return on Assets (ROA) | -66.75% | -66.75% | -53.18% | -53.15% | -42.73% | -53.91% | |
| Return on Capital Employed (ROCE) | -146.70% | -146.70% | -115.00% | -102.80% | -148.90% | -73.30% | |
| Earnings Yield | -152.51% | -39.89% | -50.64% | -86.33% | -52.20% | -32.72% | |
| FCF Yield | -138.90% | -36.33% | -49.11% | -95.47% | -55.47% | -25.60% | |
| Buyback Yield / Dilution | -126.97% | -126.97% | -70.22% | -56.71% | -47.49% | -54.32% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.